Rosdah, Ayeshah Augusta and Holien, Jessica K. and Delbridge, Lea M.D. and Dusting, Gregory J. and Lim, Shiang Y. (2016) Mitochondrial fission ? a drug target for cytoprotection or cytodestruction? Pharmacology Research and Perspectives, 4 (3). pp. 1-19. ISSN e00235
Preview |
Text
Ayeshah_Augusta_Rosdah-FK_Unsri.pdf Download (1MB) | Preview |
Abstract
Mitochondria are morphologically dynamic organelles constantly undergoing processes of fission and fusion that maintain integrity and bioenergetics of the organelle: these processes are vital for cell survival. Disruption in the balance of mitochondrial fusion and fission is thought to play a role in several pathological conditions including ischemic heart disease. Proteins involved in regulating the processes of mitochondrial fusion and fission are therefore potential targets for pharmacological therapies. Mdivi-1 is a small molecule inhibitor of the mitochondrial fission protein Drp1. Inhibiting mitochondrial fission with Mdivi-1 has proven cytoprotective benefits in several cell types involved in a wide array of cardiovascular injury models. On the other hand, Mdivi-1 can also exert antiproliferative and cytotoxic effects, particularly in hyperproliferative cells. In this review, we discuss these divergent effects of Mdivi-1 on cell survival, as well as the potential and limitations of Mdivi-1 as a therapeutic agent.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | mitochondria, fission, drug target |
| Subjects: | R Medicine > RM Therapeutics. Pharmacology > RM1-950 Therapeutics. Pharmacology |
| Divisions: | 04-Faculty of Medicine > 11201-Medicine (S1) |
| Depositing User: | dr. Ayeshah Augusta Rosdah |
| Date Deposited: | 20 Jan 2020 09:01 |
| Last Modified: | 20 Jan 2020 09:01 |
| URI: | http://repository.unsri.ac.id/id/eprint/24684 |
Actions (login required)
 |
View Item |